AbbVie recently finalized its acquisition of Cerevel Therapeutics, a move that will significantly expand the company's presence in the neuroscience and neurology space.
Cerevel Therapeutics will now operate as a subsidiary of AbbVie, a global biopharmaceutical company.
The acquisition brings a robust pipeline of innovative treatments for neurological disorders, including Parkinson's disease and schizophrenia, to AbbVie's portfolio.
This strategic move positions AbbVie to address unmet needs in the neuroscience market.
For more insights, see: Abbvie Acquires Cerevel
Acquisition News
AbbVie has completed its acquisition of Cerevel Therapeutics, a clinical-stage biopharmaceutical company specializing in neuroscience diseases. The acquisition is valued at $8.7 billion.
AbbVie's acquisition of Cerevel strengthens its foundation in neuroscience and positions it to deliver sustainable long-term performance into the next decade and beyond. This is according to AbbVie's CEO, Robert A. Michael.
Cerevel's pipeline products are aimed at neurological and psychiatric conditions such as Parkinson's disease, schizophrenia, and mood disorders. These conditions have significant unmet need, and AbbVie's acquisition of Cerevel brings new hope for patients suffering from them.
Emraclidine is a potential best-in-class, next-generation antipsychotic developed by Cerevel. It's a positive allosteric modulator of the muscarinic M4 receptor that has shown promising efficacy and safety in a Phase Ib study.
Alibaba Completes Cerevel Acquisition
AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline.
The acquisition is valued at $45 per share in cash, or a total equity value of approximately $8.7 billion.
AbbVie's acquisition of Cerevel strengthens their foundation in neuroscience and positions them to deliver sustainable long-term performance into the next decade and beyond.
Cerevel's pipeline comprises multiple programs across several neurological and psychiatric conditions with significant unmet need, including schizophrenia, Parkinson's disease, and mood disorders.
Among Cerevel’s promising drug candidates is emraclidine, a potential best-in-class, next-generation antipsychotic.
Emraclidine is a positive allosteric modulator (PAM) of the muscarinic M4 receptor that is currently being studied for treating schizophrenia.
A Phase Ib study showed that emraclidine demonstrated promising efficacy and safety.
It is currently completing two Phase II trials.
CVL-354 is a potential best-in-class kappa opioid receptor (KOR) antagonist currently in Phase I development.
This drug candidate can potentially provide significantly improved efficacy and tolerability compared to existing treatments for major depressive disorder (MDD).
Darigabat, currently in Phase II development, is an alpha 2/3/5 selective γ-aminobutyric acid type A receptor PAM for treatment-resistant epilepsy and panic disorder.
AbbVie's new Cerevel colleagues share their commitment to deliver meaningful change for patients living with neurological and psychiatric conditions.
Worth a look: What Is Share Swap
News
AbbVie has completed its acquisition of Cerevel Therapeutics for $8.7 billion, expanding its neuroscience pipeline.
The acquisition includes Cerevel's clinical-stage assets, which complement AbbVie's emerging neuroscience pipeline and branded products for treating psychiatric disorders, migraine, and Parkinson's disease.
AbbVie's CEO, Robert A. Michael, stated that the acquisition strengthens the company's foundation in neuroscience and positions it for sustainable long-term performance.
Cerevel's pipeline includes multiple programs across several neurological and psychiatric conditions, including schizophrenia, Parkinson's disease, and mood disorders.
Emraclidine, a potential best-in-class antipsychotic, is currently in Phase II trials and has shown promising efficacy and safety in a Phase Ib study.
CVL-354, a kappa opioid receptor antagonist, is in Phase I development and aims to provide improved efficacy and tolerability for major depressive disorder.
Darigabat, an alpha 2/3/5 selective GABAA receptor PAM, is in Phase II development for treatment-resistant epilepsy and panic disorder.
Tavapadon, a dopamine D1/D5 selective partial agonist, is in Phase III studies for Parkinson's disease and has demonstrated potential as both monotherapy and adjunctive treatment.
AbbVie's acquisition of Cerevel Therapeutics is expected to have a significant impact on the company's neuroscience portfolio.
The acquisition is valued at $45 per share in cash, or a total equity value of approximately $8.7 billion.
Featured Images: pexels.com
